BLAINJECTIONINJECTABLE
Approved
May 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
KEVZARA (sarilumab) by Sanofi is interleukin 6 receptor antagonists [moa]. First approved in 2017.
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KEVZARA (sarilumab) is a monoclonal antibody that antagonizes the interleukin-6 receptor, reducing inflammatory signaling in rheumatoid arthritis. It is administered via subcutaneous injection and is indicated for moderate-to-severe rheumatoid arthritis in adults. The drug blocks IL-6 signaling, a key driver of joint inflammation and disease progression.
$0.11BPart D
PeakStable
The product is at peak commercial maturity with ~$110M in annual Part D spending; teams are focused on defending market share against established competitors rather than expansion.
Mechanism of Action
Interleukin 6 Receptor Antagonists
Pharmacologic Class:
Interleukin-6 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events
Started Oct 2026
41 enrolled
Any Advanced Solid Tumors
Phase 1b/2 Study of IV Sarilumab in Adult With RA
Started Jul 2026
140 enrolled
Rheumatoid Arthritis
Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica
Started May 2026
300 enrolled
Polymyalgia Rheumatica
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.
Started Aug 2023
56 enrolled
Lung Cancer
Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19
Started Apr 2020
60 enrolled
COVID-19 Drug Treatment
Worked on KEVZARA at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.